_id

683a1660c782e11e38d1b3ac

id

10595

title

2018 Leibovich Model for Renal Cell Carcinoma (RCC)

full_title

2018 Leibovich Model for Renal Cell Carcinoma (RCC)

short_title

2018 Leibovich Model for RCC

med_description

Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC).

short_description

RCC survival.

slug

2018-leibovich-model-renal-cell-carcinoma-rcc

description

The 2018 Leibovich Model for Renal Cell Carcinoma predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC).

keywords

2018 Leibovich Model for Renal Cell Carcinoma, 2018 Leibovich Model for RCC, Leibovich model, renal cell carcinoma, rcc, cancer, kidney cancer, clear cell renal cell carcinoma, clear cell RCC, ccRCC, papillary renal cell carcinoma, papillary RCC, papRCC, chromophobe renal cell carcinoma, chromophobe RCC, chrRCC, nonmetastatic RCC, nonmetastatic ccRCC, nonmetastatic papRCC, nonmetastatic chrRCC, progression-free survival, progression free survival, cancer-specific survival, cancer specific survival, RCC survival, cancer survival

complaint

[ "Abdominal Mass", "Abdominal Pain", "Cancer", "Fatigue", "Fever", "Flank Pain", "Hematuria", "Shortness of Breath", "Weight Loss/Gain" ]

formula

Scoring of features for clear cell RCC (ccRCC) is as follows: *Tumor thrombus level was defined by theNeves and Zinckeclassification. Scoring of features for papillary RCC (papRCC) is as follows: Scoring of features for chromophobe RCC (chrRCC) is as follows:

evidence

measurements

[]

information

Interpretation:

refrences

{ "Clinical Practice Guidelines": [ { "href": "https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2024.pdf", "text": "EAU Guidelines on Renal Cell Carcinoma. EAU Guidelines Office; 2024." } ], "Manufacturer Website": [], "Original/Primary Reference": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/29398265/", "text": "Leibovich BC, Lohse CM, Cheville JC, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol. 2018;73(5):772-780." } ], "Other References": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/12655523/", "text": "Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-1671." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/35140049/", "text": "Rosiello G, Larcher A, Fallara G, et al. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urol Oncol. 2022;40(6):271.e19-271.e27." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/33883645/", "text": "Mattila KE, Laajala TD, Tornberg SV, et al. A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Sci Rep. 2021;11(1):8650." } ], "Outcomes": [], "Validation": [ { "href": "https://pubmed.ncbi.nlm.nih.gov/37046815/", "text": "Piccinelli ML, Morra S, Tappero S, et al. Critical appraisal of leibovich 2018 and grant models for prediction of cancer-specific survival in non-metastatic chromophobe renal cell carcinoma. Cancers (Basel). 2023;15(7):2155." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/37803521/", "text": "Schmeusser BN, Patil DH, Nicaise EH, et al. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race. Cancer. 2024;130(3):453-466." }, { "href": "https://pubmed.ncbi.nlm.nih.gov/30905510/", "text": "Lee HJ, Lee A, Huang HH, Lau WKO. External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population. Urol Oncol. 2019;37(6):356.e9-356.e18." } ], "Validations": [] }

pearls

• Originally published in 2003 and revised in 2018 to reflect contemporary pathology and outcomes.
• The Mayo Clinic derivation cohort was predominantly White, although subsequent external validations demonstrate broader applicability.
• Scoring is independent of evolving American Joint Committee on Cancer (AJCC) staging, relying instead on specific pathologic features.

usecase

Apply after partial or radical nephrectomy for localized or locally‑advanced, non‑metastatic renal cell carcinoma (RCC) once final pathology is available, to stratify risk for progression and death.

reasons

Estimates 5‑, 10‑ and 15‑year progression‑free (PFS) and cancer‑specific survival (CSS) from the date of surgery, which can guide surveillance imaging schedules and decisions on adjuvant therapy or trial enrollment. Uses clinicopathologic data readily available after surgical resection. Outperforms pathologic staging alone. Incorporates the three most common RCC subtypes, whereas many models address only ccRCC. Used for clinical trial selection. Recommended in the2024 European Association of Urology (EAU) guidelines on renal cell carcinoma.

next_advice

• This tool should be used in conjunction with clinical expertise, specialist consultation, and patient preferences to direct treatment and monitoring.
• In general, risk estimates can guide:
  
  • Surveillance intensity.
  • Adjuvant therapy use, including immunotherapies.
  • Prognosis counselling.
  • Comorbidity management.
• Scores may also identify individuals who are appropriate for clinical trials.

next_actions

next_management

diseases

[ "Renal Cell Carcinoma" ]

input_schema

[ { "conditionality": null, "default": null, "label_en": "<p>Type of RCC</p>", "mdcalc_info_concept": null, "name": "rcc_type", "option_fhir_rules": null, "optional": false, "options": [ { "label": "Clear cell RCC (ccRCC)", "value": 0 }, { "label": "Papillary RCC (papRCC)", "value": 1 }, { "label": "Chromophobe RCC (chrRCC)", "value": 2 } ], "show_points": false, "tips_en": "", "type": "radio" }, { "conditionality": "rcc_type == 0", "default": null, "label_en": "<p>Age at surgery, years</p>", "md_calc_info_concept": null, "name": "age", "option_fhir_rules": null, "optional": false, "options": [ { "label": "<60", "value": 0 }, { "label": "≥60", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p><calculator id=\"3170\">ECOG</calculator> status</p>", "md_calc_info_concept": null, "name": "ecog", "option_fhir_rules": null, "optional": false, "options": [ { "label": "0", "value": 0 }, { "label": "≥1", "value": 2 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Constitutional symptoms</p>", "md_calc_info_concept": null, "name": "constitution", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Adrenalectomy</p>", "md_calc_info_concept": null, "name": "adrenal", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Surgical margins</p>", "md_calc_info_concept": null, "name": "margins", "option_fhir_rules": null, "optional": false, "options": [ { "label": "Negative", "value": 0 }, { "label": "Positive", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0 || rcc_type == 1", "default": 0, "label_en": "<p>Tumor grade</p>", "md_calc_info_concept": null, "name": "grade", "option_fhir_rules": null, "optional": false, "options": [ { "label": "1", "value": 0 }, { "label": "2", "value": 1 }, { "label": "3", "value": 2 }, { "label": "4", "value": 3 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Coagulative necrosis</p>", "md_calc_info_concept": null, "name": "necrosis", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 2 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0 || rcc_type == 2", "default": 0, "label_en": "<p>Sarcomatid differentiation</p>", "md_calc_info_concept": null, "name": "sarc", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Tumor size, cm</p>", "mdcalc_info_concept": null, "name": "size", "option_fhir_rules": null, "optional": false, "options": [ { "label": "≤4", "value": 0 }, { "label": ">4 to ≤7", "value": 1 }, { "label": ">7 to ≤10", "value": 2 }, { "label": ">10", "value": 3 } ], "show_points": false, "tips_en": "", "type": "radio" }, { "conditionality": "rcc_type == 0 || rcc_type == 1 || rcc_type == 2", "default": 0, "label_en": "<p>Perinephric/renal sinus fat invasion</p>", "md_calc_info_concept": null, "name": "fat", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0 || rcc_type == 1", "default": 0, "label_en": "<p>Tumor thrombus</p>", "mdcalc_info_concept": null, "name": "thrombus", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Level 0", "value": 1 }, { "label": "Level 1-4", "value": 2 } ], "show_points": false, "tips_en": "", "type": "radio" }, { "conditionality": "rcc_type == 0", "default": 0, "label_en": "<p>Extension beyond kidney</p>", "md_calc_info_concept": null, "name": "kidney", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 2 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "rcc_type == 0 || rcc_type == 2", "default": 0, "label_en": "<p>Nodal involvement</p>", "mdcalc_info_concept": null, "name": "nodal", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No nodal dissection", "value": 0 }, { "label": "No", "value": 0 }, { "label": "Yes", "value": 2 } ], "show_points": false, "tips_en": "", "type": "radio" } ]

instructions

Separate calculators are available for clear cell (ccRCC), papillary (papRCC), and chromophobe (chrRCC) histologies; always select the version that matches the surgical specimen.

published

2025-04-21T16:37:44.823Z

purpose

[ "Prognosis" ]

search_terms

[ "2018 Leibovich Model for Renal Cell Carcinoma", "2018 Leibovich Model for RCC", "Leibovich model", "renal cell carcinoma", "rcc", "cancer", "kidney cancer", "clear cell renal cell carcinoma", "clear cell RCC", "ccRCC", "papillary renal cell carcinoma", "papillary RCC", "papRCC", "chromophobe renal cell carcinoma", "chromophobe RCC", "chrRCC", "nonmetastatic RCC", "nonmetastatic ccRCC", "nonmetastatic papRCC", "nonmetastatic chrRCC", "progression-free survival", "progression free survival", "cancer-specific survival", "cancer specific survival", "RCC survival", "cancer survival" ]

seo

{ "keywords_en": "2018 Leibovich Model for Renal Cell Carcinoma, 2018 Leibovich Model for RCC, Leibovich model, renal cell carcinoma, rcc, cancer, kidney cancer, clear cell renal cell carcinoma, clear cell RCC, ccRCC, papillary renal cell carcinoma, papillary RCC, papRCC, chromophobe renal cell carcinoma, chromophobe RCC, chrRCC, nonmetastatic RCC, nonmetastatic ccRCC, nonmetastatic papRCC, nonmetastatic chrRCC, progression-free survival, progression free survival, cancer-specific survival, cancer specific survival, RCC survival, cancer survival", "meta_description_en": "The 2018 Leibovich Model for Renal Cell Carcinoma predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC)." }

specialty

[ "Hematology and Oncology", "Nephrology", "Urology" ]

departments

[ "Oncologic", "Renal", "Urinary" ]

tags

[]

version_number

1

versions

[]

related

[]

ismed

false

section

[ "whenToUseViewed", "pearlsPitfallsViewed", "whyUseViewed", "nextStepsViewed", "evidenceViewed" ]

cleaned_departments

[ "oncology", "urology", "urology" ]

cleaned_use

[ "Apply after partial or radical nephrectomy for localized or locally‑advanced, non‑metastatic renal cell carcinoma (RCC) once final pathology is available, to stratify risk for progression and death." ]

pub

false